PT-141
Also known as: Bremelanotide
Melanocortin Receptor Peptide
COMPOUND CLASS
Melanocortin receptor agonist peptide
PRIMARY PATHWAY
MC3R and MC4R signaling in the central nervous system
PRIMARY AREAS OF RESEARCH
Central sexual-response signaling, melanocortin biology
RESEARCH STATUS
Studied in randomized human trials; an approved formulation exists
EVIDENCE LEVEL
Moderate
OTHER NAMES
Bremelanotide
What Is PT-141?
PT-141, also known as bremelanotide, is a lab-made peptide related to a natural hormone fragment (alpha-MSH) that interacts with a family of receptors called melanocortin receptors. These receptors are found in several tissues, including the brain.
It is scientifically notable because it acts in the nervous system rather than on blood vessels. Most earlier compounds studied in the context of sexual response worked by affecting blood flow; PT-141 is studied as a model for arousal signaling that starts in the brain.
- What it is
- A synthetic peptide (bremelanotide) that acts on melanocortin receptors in the brain.
- Category
- Hormonal and neuroendocrine research peptide.
- Main system involved
- The central melanocortin system, particularly MC4 receptors in the brain.
- Research interest
- Central pathways involved in sexual arousal and neuroendocrine signaling.
- Research status
- Studied in human clinical trials; mechanism is central rather than vascular.
Why Are Researchers Interested?
A central, not vascular, mechanism
It gives researchers a way to study arousal pathways in the brain rather than circulatory responses.
Melanocortin receptor biology
The MC4 receptor is involved in appetite, energy balance, and sexual function, making it a broadly interesting target.
Human clinical data exists
It has been evaluated in controlled human trials, which is a higher evidence level than purely preclinical peptides.
Receptor selectivity questions
Researchers continue to study which melanocortin receptor subtypes drive which effects.
How It Works
Sexual arousal begins as a signal in the brain before anything happens elsewhere in the body. PT-141 is studied because it interacts with receptors located in brain regions that help coordinate those signals.
When the peptide docks with an MC4 receptor, the cell produces an internal second messenger (cAMP) that changes the neuron's activity. In simple terms, the compound is thought to influence the brain's arousal signaling rather than mechanically increasing blood flow.
Current Areas of Research
Central arousal pathways
How brain circuits initiate and coordinate sexual response.
Melanocortin receptor subtypes
Determining which receptors, MC3 or MC4, are responsible for which effects.
Neuroendocrine signaling
Interactions between the brain and hormone-releasing systems.
Comparative mechanisms
How central pathways differ from blood-flow-based mechanisms.
Tolerability profiles
Documented effects such as nausea and flushing observed in trials.
What Does the Evidence Actually Say?
Moderate — randomized controlled human trials have been published for a specific approved indication, while broader research questions about melanocortin signaling remain open.
Side Effects & Safety Research
Documented in research
- Nausea, flushing, and headache are the most commonly reported effects in published trials.
- Transient blood-pressure changes have been documented and studied.
Possible or theoretical
- Skin darkening (hyperpigmentation) has been reported with melanocortin-pathway compounds.
Where evidence is insufficient
- Long-term repeated-use data outside the studied indication is limited.
What We Don't Know Yet
- The full downstream chain of events after receptor activation is not completely mapped.
- Responses vary considerably between individuals, and the biological reasons are unclear.
- Long-term effects of repeated melanocortin receptor activation are not well characterized.
- Effects on appetite and pigmentation, other melanocortin functions, are incompletely studied in this context.
Frequently Asked Questions
Research References
- Hadley ME and Dorr RT. Melanocortin peptide therapeutics: historical milestones and clinical studies. Peptides, 2006.
- King SH et al. Melanocortin receptor agonists and sexual function research. International Journal of Impotence Research, 2007.
- Cone RD. Anatomy and regulation of the central melanocortin system. Nature Neuroscience, 2005.
Key Takeaway
PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin receptors in the brain, making it a research model for arousal pathways that begin in the nervous system rather than the circulatory system. It has been examined in human clinical trials, and questions remain about receptor selectivity, individual variability, and long-term effects.
Related Research
This information is provided for educational purposes only and summarizes current areas of scientific research. It is not medical advice, a treatment recommendation, or an instruction for personal use. Research findings may be preliminary, limited, or subject to change as new evidence becomes available.